Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Drops By 38.6%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a large drop in short interest in April. As of April 15th, there was short interest totaling 71,193 shares, a drop of 38.6% from the March 31st total of 115,865 shares. Based on an average daily trading volume, of 156,443 shares, the days-to-cover ratio is currently 0.5 days. Approximately 1.5% of the shares of the company are short sold.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

A number of large investors have recently made changes to their positions in SHPH. Connective Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals during the 3rd quarter valued at about $357,000. Ikarian Capital LLC bought a new position in shares of Shuttle Pharmaceuticals during the 4th quarter valued at approximately $124,000. Boothbay Fund Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the 4th quarter valued at approximately $37,000. Finally, Geode Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the 4th quarter valued at approximately $26,000. 4.58% of the stock is currently owned by institutional investors.

Shuttle Pharmaceuticals Price Performance

Shuttle Pharmaceuticals stock opened at $1.03 on Monday. The business has a 50-day simple moving average of $0.91 and a two-hundred day simple moving average of $1.72. The company has a market cap of $5.76 million, a P/E ratio of -0.09 and a beta of -0.53. Shuttle Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $11.25.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.06 earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .